4.6 Article

20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia

Journal

AMERICAN JOURNAL OF PSYCHIATRY
Volume 175, Issue 8, Pages 765-773

Publisher

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2018.17091001

Keywords

-

Categories

Funding

  1. Finnish Ministry of Social Affairs and Health through the developmental fund for Niuvanniemi Hospital
  2. Finnish Medicines Agency (Fimea)
  3. European Medicines Agency
  4. AstraZeneca
  5. Bristol-Myers Squibb
  6. Eli Lilly
  7. Hoffman-La Roche
  8. GlaxoSmithKline
  9. Janssen-Cilag
  10. Lundbeck
  11. Novartis
  12. Organon
  13. Otsuka
  14. Pfizer
  15. Sigrid Juselius Foundation
  16. Stanley Foundation

Ask authors/readers for more resources

Objective: It is generally believed that after the first episode of schizophrenia, the risk of relapse decreases with time in patients who are stabilized. Many treatment guidelines recommend that after stabilization, antipsychotic treatment should be continued for 1-5 years, and longer exposure should be avoided if possible. However, there is no published evidence to substantiate this view. The authors used nationwide databases to investigate this issue. Method: Prospectively gathered nationwide register data were used to study the risk of treatment failure (psychiatric rehospitalization or death) after discontinuation of antipsychotic treatment. Multivariate Cox regression was used to assess outcomes among all patients hospitalized for the first time with a schizophrenia diagnosis in Finland during the period of 1996-2014 (N=8,719). Results: The lowest risk of rehospitalization or death was observed for patients who received antipsychotic treatment continuously (adjusted hazard ratio=1.00), followed by patients who discontinued antipsychotic use immediately after discharge from the first hospital treatment (hazard ratio=1.63,95% CI=1.52-1.75), within1 year (hazard ratio=1.88, 95% CI=1.57-2.24), within 1-2 years (hazard ratio=2.12, 95% CI=1.43-3.14), within 2-5 years (hazard ratio=3.26, 95% CI=2.07-5.13), and after 5 years (a median of 7.9 years) (hazard ratio=7.28, 95% CI=2.78-19.05). Risk of death was 174% 2214% higher among nonusers and patients with early discontinuation of antipsychotics compared with patients who received antipsychotic treatment continuously for up to 16.4 years. Conclusions: Whatever the underlying mechanisms, these results provide evidence that, contrary to general belief, the risk of treatment failure or relapse after discontinuation of antipsychotic use does not decrease as a function of time during the first 8 years of illness, and that long-term antipsychotic treatment is associated with increased survival.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available